King Pharma (KG) Beat Q3 Views by 2c
More News related to KG
- Notable 52-Week NYSE New Highs and Lows 11/19: CAH, DCI, RX, KG, MRK, TSL Highs; SNV, WNR Low
- StockPreacher.com Issues Trading Outlook for Arena Pharmaceuticals Inc.
- King Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
- Trading Outlook for ZymoGenetics Inc. Issued by StockPreacher.com
- Wedbush Upgrades ZymoGenetics (ZGEN) to Outperform; Believe ZGEN on Track to Meet 2010 Sales Estimates
King Pharmaceuticals (NYSE: KG) reports Q3 EPS of $0.29, 2 cents better than the analyst estimate of $0.27. Revenue for the quarter was $463 million, which compares to the estimate of $444.98 million.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
